Who we are What we do Who is using our data Steering committee Operating team Trialists Former contributors Publications Data sharing Update: every 2 weeks
Mapping Treatments tested
Pharmacologic treatments Nonpharmacologic treatments
Living mapping Living evidence synthesis (Vaccine RCTs) Living evidence synthesis (Vaccine RCTs - Variants) Living evidence synthesis (Observational studies - Variants)
Preventive treatments
☰

Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up to this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Of note, as of March 1, 2022, the COVID-NMA revised its protocol and reduced its scope.
Only comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: comparisons updated with new studies

Access the forest plots for the 11 treatment comparisons .

Comparisons evaluating antivirals and immunomodulators updated every two weeks.

    Anti-virals (5 comparisons)

    Monoclonal antibodies (4 comparisons)

    Other immunomodulators (1 comparisons)

Comparisons with last search date 28 February 2022 or as stated next to each comparison.

    Other antimicrobials (antibiotics, antimalarials, antiparasitics) (1 comparisons)

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment		 Full description
Treatment 1 Treatment 2
New
NCT04518410
ACTIV-2
Taiwo BO, Top Antivir Med, 2022
Full text
 Not reported/unclear

SAB-185

Placebo

 RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 42 centers in the USA N=213 N/A

Full description
New
NCT04518410
ACTIV-2
Jilg N, Top Antivir Med, 2022 a
Full text
 Not reported/unclear

Camostat Mesilate

Placebo

 RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 54 centers in the USA N=215 N/A

Full description
New
NCT04518410
ACTIV-2
Evering TH, Open Forum Infect Dis, 2021
Full text
Commentary
 Not reported/unclear

BRII-196 plus BRII-198

Placebo

 RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by multiple centers in the USA, Brazil, South Africa, Mexico, Argentina and the Philippines. N=837
Some concerns
Details

Full description
New
NCT04709835
NCT04709835, Unpublished, 2022
Full text
 Not reported/unclear

AT-527

AT-527 550 mg

Placebo

AT-527 1100 mg

 RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 12 centers in Canada, Greece, Ireland, Latvia, Spain, UK N=100
Some concerns
Details

Full description
New
NCT04575038
CRISIS2
CRISIS2, Unpublished, 2022
Full text
 Not reported/unclear

Brequinar

Placebo

 RCT Outpatients with confirmed COVID-19 (mild) treated by 14 centers in USA. N=115
Low
Details

Full description
NCT04694612
Adhikari P, Int J Infect Dis, 2022 b
Full text
Commentary
 Not reported/unclear

Remdesivir

Favipiravir

 RCT Patients with confirmed COVID-19 (moderate) admitted to 9 centers in Nepal N=20
Some concerns
Details

Full description
NCT04694612
Adhikari P, Int J Infect Dis, 2022 a
Full text
Commentary
 Not reported/unclear

Favipiravir

Placebo

 RCT Patients with confirmed COVID-19 (mild) admitted to 9 centers in Nepal N=70
Some concerns
Details

Full description
NCT04847141
NCT04847141, Unpublished, 2022
Full text
 Not reported/unclear

Hyperimmune anti-COVID-19 Intravenous Immunoglobulin 1g/2g

Placebo

 RCT Outpatients with confirmed COVID-19 (asymptomatic) treated by 5 centers in Spain. N=461
Some concerns
Details

Full description
NCT04427501
BLAZE-1
BLAZE-1, Unpublished, 2022
Full text
 Not reported/unclear

LY-CoV555+LY-CoV016

Placebo

 RCT Outpatients with confirmed COVID-19 (mild) treated by multiple centers in the USA. N=354
Low
Details

Full description
IRCT20211004052664N1
Tehrani S, Mediterr J Infect Microbes Antimicrob, 2022
Full text
Commentary
 No specific funding

Favipiravir

Standard care

 RCT Outpatients with confirmed COVID-19 (moderate) treated by a single center in Iran. N=78
Some concerns
Details

Full description